Cancer incidence rates among patiens with Multiple Sclerosis
Cancer incidence rates among patients with multiple sclerosis (MS) treated after the advent of immune therapies show an increase compared with prior generations, according to a large study of Norwegian patients with MS.
This finding suggests that clinicians should be aware of this increased risk of cancer when caring for MS patients.
With the widespread use of disease-modifying therapies (DMTs) in patients with MS, such findings are always of interest to clinicians and patients alike.
Something that's already on the mind of most people with MS is what are the long-term safety characteristics of these medicines because we're talking about a life-long therapy for most people.